Pulike Biological Engineering, Inc.

Shanghai Stock Exchange 603566.SS

Pulike Biological Engineering, Inc. Capital Expenditure for the year ending December 31, 2023: USD -42.96 M

Pulike Biological Engineering, Inc. Capital Expenditure is USD -42.96 M for the year ending December 31, 2023, a 16.91% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Pulike Biological Engineering, Inc. Capital Expenditure for the year ending December 31, 2022 was USD -51.70 M, a -3.45% change year over year.
Pulike Biological Engineering, Inc. Capital Expenditure for the year ending December 31, 2021 was USD -49.97 M, a -84.15% change year over year.
Pulike Biological Engineering, Inc. Capital Expenditure for the year ending December 31, 2020 was USD -27.14 M, a -121.87% change year over year.
Pulike Biological Engineering, Inc. Capital Expenditure for the year ending December 31, 2019 was USD -12.23 M, a -56.89% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shanghai Stock Exchange: 603566.SS

Pulike Biological Engineering, Inc.

CEO	Mr. Wei Hu
IPO Date	May 18, 2015
Location	China
Headquarters	No.15 Zhenghe Road
Employees	1,679
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.

Key trends

Past 5 years